Immunogenicity of pembrolizumab in patients with advanced tumors

BACKGROUND: Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug antibodies (ADAs), which may alter drug clea...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: van Vugt, Marianne J. H., Stone, Julie A., De Greef, “Rik” H. J. M. M., Snyder, Ellen S., Lipka, Leslie, Turner, David C., Chain, Anne, Lala, Mallika, Li, Mengyao, Robey, Seth H., Kondic, Anna G., De Alwis, Dinesh, Mayawala, Kapil, Jain, Lokesh, Freshwater, Tomoko
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6686242/
https://ncbi.nlm.nih.gov/pubmed/31395089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0663-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы